Get the Stockscreener App
33.30
0.11%
-0.1136
Ionis Pharmaceuticals Inc stock is traded at $33.30, with a volume of 190.65K.
It is down -0.11% in the last 24 hours and up +9.96% over the past month.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
See More
Previous Close:
$33.41
Open:
$33.34
24h Volume:
190.65K
Relative Volume:
0.12
Market Cap:
$5.31B
Revenue:
$803.07M
Net Income/Loss:
$-358.81M
P/E Ratio:
-13.65
EPS:
-2.44
Net Cash Flow:
$-374.21M
1W Performance:
-2.96%
1M Performance:
+9.96%
6M Performance:
-20.90%
1Y Performance:
-22.68%
1-Day Range:
$32.91
$33.84
1-Week Range:
$31.46
$34.90
52-Week Range:
$30.23
$52.34
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Name
Ionis Pharmaceuticals Inc
Sector
Industry
Phone
(760) 931-9200
Address
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
33.31 | 5.31B | 803.07M | -358.81M | -374.21M | -2.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.43 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.83 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
578.91 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.42 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.40 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-02-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-16-24 | Resumed | Jefferies | Buy |
| Jun-14-24 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Apr-10-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-02-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-23-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Sep-29-23 | Initiated | Raymond James | Strong Buy |
| Jul-31-23 | Upgrade | Citigroup | Neutral → Buy |
| Jun-07-23 | Resumed | Piper Sandler | Overweight |
| May-04-23 | Upgrade | Citigroup | Sell → Neutral |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Dec-21-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-09-22 | Resumed | Morgan Stanley | Overweight |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-01-22 | Initiated | Citigroup | Sell |
| Mar-01-22 | Initiated | Guggenheim | Buy |
| Feb-01-22 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-07-21 | Upgrade | UBS | Sell → Neutral |
| Mar-01-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Dec-16-20 | Initiated | UBS | Sell |
| Dec-15-20 | Upgrade | Cowen | Market Perform → Outperform |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Sep-02-20 | Initiated | The Benchmark Company | Hold |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Nov-07-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-10-19 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-08-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Reiterated | Stifel | Hold |
| May-08-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-06-17 | Resumed | Goldman | Sell |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Aug-09-17 | Reiterated | Stifel | Hold |
| Mar-10-17 | Downgrade | Goldman | Neutral → Sell |
| Dec-28-16 | Reiterated | BMO Capital Markets | Outperform |
| Dec-27-16 | Reiterated | Leerink Partners | Mkt Perform |
View All
Ionis Pharmaceuticals Inc Stock (IONS) Latest News
Ionis Gets Tryngolza Launch Cash From Ono Via Sapablursen License - Citeline News & Insights
Ionis Pharmaceuticals at Barclays Conference: Strategic Growth and Partnerships By Investing.com - Investing.com UK
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases - AOL
Ono earmarks $940m to gain rare blood cancer therapy from Ionis - Yahoo
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal - AOL
Ono partners with Ionis for sapablursen - The Pharma Letter
Ono pays $280M to license Ionis rare disease drug - BioPharma Dive
Oppenheimer maintains Outperform on Ionis, $78 target By Investing.com - Investing.com UK
Ionis out licenses blood disorder therapy to Ono in a deal worth up to $940M - MSN
Ionis Out-Licenses Rights for Rare Blood Cancer Drug to Ono - Zacks Investment Research
Ionis Pharmaceuticals Enters Global License Agreement With Ono Pharmaceutical for Sapablursen - Marketscreener.com
Jones Financial Companies Lllp Has $326,000 Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Cut to $47.00 by Analysts at JPMorgan Chase & Co. - Defense World
Ionis and Ono announce global license agreement for sapablursen in polycythemia vera - Quantisnow
Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera - Bluefield Daily Telegraph
Massive $940M Deal: Ionis Partners with Ono on Breakthrough Blood Cancer Treatment - StockTitan
What Analysts Are Saying About Ionis Pharmaceuticals Stock - Benzinga
IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe - Zacks Investment Research
When the Price of (IONS) Talks, People Listen - Stock Traders Daily
EU clears AZ, Ionis' Wainzua for ATTR polyneuropathy - pharmaphorum
Ionis Pharmaceuticals Says Transthyretin-Mediated Amyloidosis Treatment Gets Approval in Europe - Marketscreener.com
WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy - Quantisnow
Ionis gains EU approval for amyloidosis treatment - Investing.com India
WAINZUA (Eplontersen) Approved In The EU For The Treatment Of Hereditary Transthyretin-Mediated Amyloidosis In Adults With Stage 1 Or Stage 2 Polyneuropathy - Marketscreener.com
Leigh Syndrome Treatment Market Poised for Substantial Growth - openPR
23,703 Shares in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Bought by Proficio Capital Partners LLC - Defense World
Principal Financial Group Inc. Has $476,000 Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World
Truist Financial Corp Sells 501 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World
Ionis Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Amalgamated Bank Purchases 335 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World
Y Intercept Hong Kong Ltd Trims Stock Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World
Spinal Muscular Atrophy Market Overall Study Report 2025-2032 | - openPR
Spinal Muscular Atrophy Pipeline 2024: Key Companies, MOA, ROA, - openPR
Brokerages Set Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Price Target at $60.00 - MarketBeat
ARK Investment Management LLC Sells 359,009 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Investor Network: Ionis Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Ionis' Q4 Earnings and Sales Beat Estimates, Tryngolza Launch in Focus - MSN
FY2026 Earnings Estimate for IONS Issued By Leerink Partnrs - MarketBeat
Intellia: Balancing in vivo risk with validated targets - BioCentury
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Rhumbline Advisers - Defense World
C WorldWide Group Holding A S Has $13.98 Million Stock Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Leerink upgrades Ionis to outperform, cites Angelman drug - MSN
Ionis to present at upcoming investor conferences - Post Register
5 Undervalued Stocks That Crushed Q4 Earnings - Morningstar
Ionis Pharmaceuticals' SWOT analysis: RNA pioneer's stock faces pivotal year - Investing.com
Ionis Pharmaceuticals EVP Patrick O'Neil sells $39,046 in stock By Investing.com - Investing.com Canada
Ionis Pharmaceuticals Officer Sells Shares - TradingView
The Zacks Analyst Blog Highlights Merck, Sanofi, Regeneron and Ionis - Nasdaq
Ionis Pharmaceuticals (NASDAQ:IONS) Issues Earnings Results - MarketBeat
Ionis Pharmaceuticals’ (IONS) Buy Rating Reiterated at Needham & Company LLC - Defense World
Ionis Pharmaceuticals Reports Strong 2024 Results - TipRanks
Ionis Pharmaceuticals Inc Stock (IONS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ionis Pharmaceuticals Inc Stock (IONS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| O'NEIL PATRICK R. | EVP CLO & General Counsel |
Feb 20 '25 |
Sale |
32.35 |
1,207 |
39,046 |
56,245 |
| O'NEIL PATRICK R. | EVP CLO & General Counsel |
Feb 04 '25 |
Sale |
31.62 |
6,165 |
194,939 |
57,452 |
| Monia Brett P | Chief Executive Officer |
Feb 04 '25 |
Sale |
31.65 |
38,843 |
1,229,463 |
180,683 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):